The priority is medical fit, not pushing add-ons
6-Month Cycle: Inject 1mL per week of month 1, every other week in month 2, 1 time per month for months 3-6 (10 ML total)
When documentation is ambiguous, query the provider do not default without clinical basis
BPC-157 + TB-500, for the cartilage indication Due to the emerging chondroprotective profile of AOD-9604 (Vukmirovic-Popovic 2010), the research literature features the combination with BPC-157 and TB-500 for indications: Osteoarthritis (intra-articular formulation) Tendinopathy Chondral defects in animal models MOTS-c, metabolic support MOTS-c improves mitochondrial efficiency, released fatty acids from AOD-9604-induced lipolysis can then be more efficiently oxidized
However, it can be added to some food products and is available as an injection or oral supplement
This medication is produced and exported by AdvaCare Pharma